Endocrine Abstracts

SGLT2i drugs have been funded by the Israeli health basket since 2017 for patients with type-2-diabetes and previous cardiovascular disease, as a result of the EMPA-REG outcome studies documenting 34% reduction in all-cause mortality. In 2015 the FDA warned that SGLT2i may result in diabetic-ketoacidosis (DKA). The reported DKA cases were not typical because many had type-2-diabetes and their blood glucose was slightly increased.Objective: To describe DK...